| scholarly article | Q13442814 |
| P50 | author | Jörn Lötsch | Q43057635 |
| Nils von Hentig | Q47158847 | ||
| P2093 | author name string | Jochen Graff | |
| Sebastian Harder | |||
| Michael Schmidt | |||
| Gerd Geisslinger | |||
| Nils von Hentig | |||
| Alexandra Doehring | |||
| Syavash Salamat | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| opioid use disorder | Q1639178 | ||
| P304 | page(s) | 407-414 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution | |
| P478 | volume | 19 |
| Q27312296 | A review of pharmacogenetic studies of substance-related disorders |
| Q36441533 | ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics |
| Q37212865 | ANKK1, TTC12, and NCAM1 polymorphisms and heroin dependence: importance of considering drug exposure |
| Q35547601 | Addiction as a systems failure: focus on adolescence and smoking |
| Q35995415 | Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system |
| Q57462875 | Addressing Host Factors: Overview of Dependence and Addiction |
| Q45060238 | Affiliation with substance-using peers: Examining gene-environment correlations among parent monitoring, polygenic risk, and children's impulsivity |
| Q34772521 | Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2) |
| Q39016970 | Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment |
| Q42180472 | Association between ANKK1 (rs1800497) and LTA (rs909253) Genetic Variants and Risk of Schizophrenia |
| Q38287758 | Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis |
| Q44351387 | Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies |
| Q37401604 | Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction |
| Q33619368 | Behavioral and Neural Manifestations of Reward Memory in Carriers of Low-Expressing versus High-Expressing Genetic Variants of the Dopamine D2 Receptor |
| Q30417717 | Breaking barriers in the genomics and pharmacogenetics of drug addiction |
| Q36928874 | Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? |
| Q36354160 | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study |
| Q33903933 | Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response |
| Q28833594 | Disagreement between two common biomarkers of global DNA methylation |
| Q52316493 | Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson's Disease. |
| Q34140370 | Endogenous opiates and behavior: 2009 |
| Q37711120 | Epigenetics and biomarkers in the staging of neuropsychiatric disorders |
| Q90451707 | Examining the link between reward and response inhibition in individuals with substance abuse tendencies |
| Q35686543 | Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction |
| Q37846139 | Genetic variability of pain perception and treatment--clinical pharmacological implications |
| Q37986616 | Genetics of dopamine receptors and drug addiction |
| Q38184547 | Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis |
| Q54562217 | Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. |
| Q34662050 | Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse |
| Q36580025 | Is food addiction a valid and useful concept? |
| Q35087543 | Nerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment |
| Q38479762 | Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land? |
| Q36849881 | Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). |
| Q48616605 | Obesity and the brain: how convincing is the addiction model? |
| Q36499673 | Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics |
| Q39225935 | Opioid maintenance, weaning and detoxification techniques: where we have been, where we are now and what the future holds |
| Q36684038 | Opioids for chronic pain: a knowledge assessment of nonpain specialty providers. |
| Q34970259 | PharmGKB summary: dopamine receptor D2 |
| Q47425192 | Pharmacogenetics of Methadone Response |
| Q38222510 | Pharmacogenomics of methadone maintenance treatment |
| Q41822191 | Predicting substance use in emerging adulthood: A genetically informed study of developmental transactions between impulsivity and family conflict |
| Q37223916 | Relationship among methadone dose, polymorphisms of dopamine D2 receptor and tri-dimensional personality questionnaire in heroin-addicted patients |
| Q51849418 | Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. |
| Q54360692 | Sex-specific effects of naturally occurring variants in the dopamine receptor D2 locus on insulin secretion and type 2 diabetes susceptibility. |
| Q46025040 | The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer's in Aging African-Americans. |
| Q33579769 | The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction |
| Q37661379 | The dopaminergic reward system and leisure time exercise behavior: a candidate allele study |
| Q30277983 | The significant association of Taq1A genotypes in DRD2/ANKK1 with smoking cessation in a large-scale meta-analysis of Caucasian populations |
| Q42201173 | Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions |
| Q37685052 | When higher doses in opioid replacement treatment are still inadequate - association to multidimensional illness severity: a cohort study |
| Q37329865 | Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note |
| Q44346717 | β-Arrestin2 influences the response to methadone in opioid-dependent patients. |
Search more.